Lipella Pharmaceuticals Inc. is a biotechnology company that creates drugs by improving the active agents in generic drugs for various uses. They are currently developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial to treat radiation-induced hemorrhagic cystitis, and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is situated in Pittsburgh, Pennsylvania.